ReviewCritical reviews in oncology/hematology2012
Eribulin -- a review of preclinical and clinical studies.
Review in Critical reviews in oncology/hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors.Cancer chemotherapy and pharmacology · 2024Trial
- Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Cancer immunology, immunotherapy : CII · 2024Trial
- Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).Breast cancer (Tokyo, Japan) · 2018Trial
- Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.Cancer chemotherapy and pharmacology · 2015Trial
- Review
- Modern synthetic pathways towards eribulin and its subunits.Beilstein journal of organic chemistry · 2026Review
- ERK-driven autophagy enhances synergy of eribulin and cisplatin in triple-negative breast cancer.Oncology letters · 2025Article
- A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin.Journal of pharmaceutical health care and sciences · 2025Article
- Eribulin exerts multitarget antineoplastic activity in glioma cells.Pharmacological reports : PR · 2025Article
- The Effectiveness and Adverse Events of Eribulin Monotherapy in Indonesian Metastatic Breast Cancer (MBC) Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin.Microbiome research reports · 2025Article
- Immunomodulatory Effects of Halichondrin Isolated from Marine Sponges and Its Synthetic Analogs in Oncological Applications.Marine drugs · 2024Review
- Eribulin in breast cancer: Current insights and therapeutic perspectives.World journal of experimental medicine · 2024Review
- Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.Cancer research communications · 2024Article
- Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells.Current issues in molecular biology · 2023Article
- Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice.Bone reports · 2023Article
- Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft.Scientific reports · 2023Article
- Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.Molecular cancer therapeutics · 2023Article
- Article
- Eribulin improves tumor oxygenation demonstrated byEuropean journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.